Sucampo Announces FDA Approval of an sNDA for RESCULA® (unoprostone isopropyl)
06:45 EST 12 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Sucampo Pharmaceuticals, Inc. (“Sucampo” or “the Company”) (NASDAQ:
SCMP) today announced that it has received approval of an sNDA for
RESCULA® (unoprostone isopropyl ophthalmic solution) 0.15%
for the lowering of intra...
Other Sources for this Article
Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
staylor@sucampo.com
More From BioPortfolio on "Sucampo Announces FDA Approval of an sNDA for RESCULA® (unoprostone isopropyl)"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
